Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P40189
UPID:
IL6RB_HUMAN
Alternative names:
CDw130; Interleukin-6 signal transducer; Membrane glycoprotein 130; Oncostatin-M receptor subunit alpha
Alternative UPACC:
P40189; A0N0L4; Q5FC04; Q9UQ41
Background:
Interleukin-6 receptor subunit beta, also known as CDw130, plays a pivotal role in signal transduction for a variety of cytokines, including IL6, LIF, and OSM. It facilitates the formation of a high-affinity receptor complex, activating JAK-MAPK and JAK-STAT3 signaling pathways. This activation is crucial for immune response, hematopoiesis, and bone metabolism. The protein is also essential for embryonic development and the survival of motor and sensory neurons.
Therapeutic significance:
Interleukin-6 receptor subunit beta is implicated in several immunologic disorders, such as Hyper-IgE recurrent infection syndrome and Stuve-Wiedemann syndrome. Its involvement in these diseases, characterized by recurrent infections, skeletal abnormalities, and immunodeficiency, underscores its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies.